Additionally, in the case of BRAF-mutant melanoma and colorectal cancer lines treated with vemurafenib, GCN2 adopted a cytoprotective role: both cancers regained sensitivity to the drug after shRNA knockdown of GCN2, making this kinase a possible target to combat vemurafenib resistance [29]. Here, EIF2AK4 is linked to melanoma.